Cartesian Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has announced its participation in three upcoming investor conferences in February and March 2025:

• H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference - February 25, 2025, at 1:00 p.m. ET (fireside chat)
• TD Cowen 45th Annual Health Care Conference - March 3, 2025, at 1:50 p.m. ET in Boston, MA (presentation)
• Leerink Global Healthcare Conference - March 10, 2025, at 8:40 a.m. ET in Miami, FL (fireside chat)

Live webcasts of these events will be available in the Events section of Cartesian Therapeutics' website, with archived replays accessible for a time.

FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March:

• A fireside chat at the H.C. Wainright & Co. 3^rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025
• A presentation at the TD Cowen 45^th Annual Health Care Conference at 1:50 p.m. ET on Monday, March 3, 2025 in Boston, MA
• A fireside chat at the Leerink Global Healthcare Conference at 8:40 a.m. ET on Monday, March 10, 2025 in Miami, FL
  

A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Investor Contact

Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact

David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

What investor conferences will Cartesian Therapeutics (RNAC) attend in February and March 2025?

Cartesian Therapeutics will participate in three conferences: H.C. Wainright Cell Therapy Virtual Conference (Feb 25), TD Cowen Health Care Conference (Mar 3), and Leerink Global Healthcare Conference (Mar 10).

How can investors watch Cartesian Therapeutics' (RNAC) conference presentations?

Investors can watch live webcasts of the presentations through the Events section of Cartesian Therapeutics' website (www.cartesiantherapeutics.com). Archived replays will also be available for a time.

What is the schedule for RNAC's conference presentations in March 2025?

In March 2025, RNAC will present at the TD Cowen Conference on March 3 at 1:50 p.m. ET in Boston, and participate in a fireside chat at the Leerink Conference on March 10 at 8:40 a.m. ET in Miami.

Which virtual conferences will RNAC participate in during February 2025?

RNAC will participate in the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference on February 25, 2025, at 1:00 p.m. ET.